Isoquercetin in Sickle Cell Anemia

Sickle Cell Disease Clinical Trial

Official title: Single-arm Phase 2 Study of Oral Isoquercetin in Sickle Cell Disease

Status Withdrawn

Clinical Trial Summary

This research study is being done to assess the safety and effectiveness of isoquercetin to reduce levels of soluble P-Selectin in patients with sickle cell disease. Isoquercetin is a naturally occurring flavonoid-or vitamin. You will find quercetin and isoquercetin in fruits and vegetables.

The names of the study drug involved in this study are/is:

• Isoquercetin

Clinical Trial Description

This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the effect of oral isoquercetin on biomarkers of endothelial and platelet activation, inflammation and ongoing blood coagulation.

• The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

• The names of the study drug involved in this study are/is: Isoquercetin

• Participants will receive study treatment for 1 year and will be followed for 30 days after the last dose.

• This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

• The U.S. Food and Drug Administration (FDA) has not approved isoquercetin as a treatment for any disease. ;

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease
• Sickle Cell-Beta0-Thalassemia
• Thalassemia

• NCT number: NCT04474626
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 2020
• Completion date: December 31, 2024